Ironwood Pharmaceuticals testing digital therapeutics opportunity with Pear Therapeutics
Outcome-Based Contracting Acceptance Grows in market with the concept of taking on financial risk on complex contracts as a result of market pressure combined with more familiarity. Outcome-based contracts between pharma companies and health insurers are becoming increasingly popular. In 2016, Novartis, Amgen, and Sanofi publicized risk-sharing, value-based, outcomes-based, or pay-for-performance deals, all of which vary […]
Increasing Demand for Drug Based Outcomes – Outcome-based contracts are a relatively new and growing contracting methodology focused on shifting reimbursement from volume to value. The contracts are between a health plan and manufacturer where reimbursement is dependent on pre-defined outcome metrics focused on improving patient responses/health. Currently, the relationship between the pharmaceutical manufacturer, the […]
While the Pharmaceutical Industry has been experiencing many shifts and changes, it is still a 21st Century Growth Industry based on the stats, facts and trends put out by Pharm Exec.More growth expected… Basic science of genomics and biology are leading to a discovery of treatments which are advanced by using the body’s own immune […]
How a company works with and contracts with SPs will have to be rethought as a result of the initial Department of Justice (DoJ) settlement with BioScrip and ongoing investigation of Novartis in their marketing practices. When Novartis launched Exjade, it created a limited distribution network, including BioScrip and two other specialty pharmacies selected by […]
How a company works with and contracts with SPs will have to be rethought as a result of the initial Department of Justice (DoJ) settlement with BioScrip and ongoing investigation of Novartis in their marketing practices. When Novartis launched Exjade, it created a limited distribution network, including BioScrip and two other specialty pharmacies selected by […]